CyberKnife S7 system (Image from Accuray)
Accuray (NSDQ:ARAY) announced today that it launched its CyberKnife S7 system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Using real-time artificial intelligence-driven motion tracking and synchronization, CyberKnife S7 offers treatments for SRS and SBRT in as little as 15 minutes, according to a news release.
The system’s AI adapts radiation delivery to patient and/or tumor movement throughout the course of treatment while offering more positions from which radiation beams can be delivered, giving physicians the ability to maximize radiation doses to the tumor and minimize doses to the surrounding healthy tissues, according to a news release.
Sunnyvale, Calif.-based Accuray touts its next-generation system from the CyberKnife platform as capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders.
Geisinger Cancer Institute, led by its chairman of radiation oncology Dr. Anand Mahadevan, is the first center in the world to treat patients with the CyberKnife S7 system.
“We are gratified to have achieved this important CyberKnife System milestone with the support from Dr. Mahadevan and his team,” Accuray president & CEO Joshua Levine said in the release. “The CyberKnife system has continued to evolve since the first patient was treated more than 25 years ago and it remains the ‘go-to’ device for clinicians who want to confidently deliver precise and accurate stereotactic treatments on a day-in, day-out basis.
“With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours.”